AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10202741 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17-beta estradiol 50 micrograms/d plus Ossein-hydroxyapatite compound 3.32 g/d
Number of subjects: 96
Study 10202741 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 96
Study 8596479 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized incremental exercise test
Number of subjects: 16
Study 8596479 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemic diabetic patients
Number of subjects: 16
Study 8596479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic diabetic patients
Number of subjects: 16
Study 8596479 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal levels of power output
Number of subjects: 16
Study 1771100 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin (200 mg, 400 mg, 600 mg)
Number of subjects: 7
Study 1771100 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg, 50 mg, 75 mg)
Number of subjects: 7
Study 1771100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7200737 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (10 mg)
Number of subjects: 10
Study 7200737 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg)
Number of subjects: 10
Study 30657812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (temperature, 33.0 ± 1.0°C) maintained for at least 72 hours after hemicraniectomy
Number of subjects: 50
Study 30657812 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 50
Study 30657812 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Number of subjects: 50
Study 28084889 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened population (FOBT screening)
Number of subjects: 500000
Study 28084889 — intervention group
Group type: COMPARATOR
Intervention: Control population (no screening)
Number of subjects: 500000
Study 25922302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 0
Study 25922302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23350696 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SQ) insulin
Number of subjects: 33
Study 23350696 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) insulin
Number of subjects: 33
Study 23350696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 21457235 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP0004 (0.63 mg emitted dose; 1.0 mg nominal dose)
Number of subjects: 903
Study 19629292 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program (PEP): 40 minutes of aerobic exercises performed 3x/week for 3 months at 70% of VO2max, and muscular exercises at 40% of maximal voluntary contraction (MVC)
Number of subjects: 88
Study 19629292 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): No participation in the physical exercise program
Number of subjects: 88
Study 17359519 — intervention group
Group type: EXPERIMENTAL
Intervention: Two auricular acupressure beads (Group A)
Number of subjects: 24
Study 17359519 — intervention group
Group type: EXPERIMENTAL
Intervention: One auricular acupressure bead (Group B)
Number of subjects: 24
Study 17359519 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Group C)
Number of subjects: 24
Study 15013599 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz electrical stimulation
Number of subjects: 7
Study 15013599 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 Hz electrical stimulation
Number of subjects: 7
Study 11511435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (atrio-bi-ventricular)
Number of subjects: 800
Study 11511435 — intervention group
Group type: COMPARATOR
Intervention: Control (optimal medical therapy with diuretics, ACE inhibitors, and beta-blockers)
Number of subjects: 800
Study 9612361 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 0
Study 9612361 — intervention group
Group type: COMPARATOR
Intervention: Drug-free treatment (Control)
Number of subjects: 0
Study 9171755 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons certified specialists for at least 10 years
Number of subjects: 1399
Study 9171755 — intervention group
Group type: EXPERIMENTAL
Intervention: University hospitals
Number of subjects: 1399
Study 9171755 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 1399
Study 2694740 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (2.5-5 mg, orally or by vaginal pessary, two or three times weekly)
Number of subjects: 300
Study 840133 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-escin (Reparil)
Number of subjects: 53
Study 840133 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 53
Study 30929275 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (0-8 mM)
Number of subjects: 0
Study 28960230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMD with sarcopenia
Number of subjects: 10937
Study 28960230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BMD without sarcopenia
Number of subjects: 10937
Study 28960230 — intervention group
Group type: COMPARATOR
Intervention: Sarcopenia alone
Number of subjects: 10937
Study 25583412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 123
Study 25583412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordered polyurethane dressing
Number of subjects: 123
Study 25583412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 123
Study 25583412 — intervention group
Group type: COMPARATOR
Intervention: Control usual practice polyurethane dressing
Number of subjects: 123
Study 24197399 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, 7-week web-based intervention
Number of subjects: 59
Study 24197399 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care as usual (Control)
Number of subjects: 59
Study 21737467 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH-01
Number of subjects: 425
Study 21737467 — intervention group
Group type: COMPARATOR
Intervention: PPH-03
Number of subjects: 425
Study 19583646 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian acupressure applied every day for 10 min for two weeks
Number of subjects: 56
Study 19583646 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 56
Study 17603225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg once-daily
Number of subjects: 8
Study 17603225 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg twice-daily
Number of subjects: 8
Study 17603225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 2 mg once-daily and 1 mg twice-daily
Number of subjects: 8
Study 17603225 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 8
Study 15051842 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF crispy bars
Number of subjects: 48
Study 15051842 — intervention group
Group type: COMPARATOR
Intervention: Control crispy bars
Number of subjects: 48
Study 11561495 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THA)
Number of subjects: 99
Study 11561495 — intervention group
Group type: COMPARATOR
Intervention: Internal Fixation
Number of subjects: 99
Study 9988026 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-surface mapping (BSM)
Number of subjects: 635
Study 9988026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of BSM in a two-step algorithm
Number of subjects: 635
Study 7848799 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 5
Study 3075109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day for 5 weeks)
Number of subjects: 70
Study 3075109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30444801 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (10 minutes, 5 minutes per leg, using sweet almond oil)
Number of subjects: 66
Study 30444801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 66
Study 29231584 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture at zusanli (ST 36) for 30 min once a day for 3 days
Number of subjects: 60
Study 29231584 — intervention group
Group type: COMPARATOR
Intervention: Granisetron hydrochloride injection, 3 mg before and after cisplatin chemotherapy, for 3 days
Number of subjects: 60
Study 29231584 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture
Number of subjects: 60
Study 29231584 — intervention group
Group type: COMPARATOR
Intervention: Granisetron hydrochloride injection
Number of subjects: 60
Study 29231584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 26186566 — intervention group
Group type: EXPERIMENTAL
Intervention: 150,000 IU cholecalciferol
Number of subjects: 50
Study 26186566 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU cholecalciferol
Number of subjects: 50
Study 26186566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of cholecalciferol
Number of subjects: 50
Study 23925936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined splint/stretching intervention
Number of subjects: 124
Study 23925936 — intervention group
Group type: COMPARATOR
Intervention: Normative data (age- and sex-matched)
Number of subjects: 124
Study 21903745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy with cisplatin (100 mg/m2 on days 1 and 29, vinblastine at 5 mg/m2 per week for 5 weeks) and TRT (63 Gy delivered as once-daily fractions beginning on day 50)
Number of subjects: 610
Study 21903745 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin (100 mg/m2) and TRT (63 Gy delivered as once-daily fractions beginning on day 1)
Number of subjects: 610
Study 21903745 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy with cisplatin (50 mg/m2 on days 1, 8, 29, and 36) and oral etoposide (50 mg twice daily for 10 weeks on days 1, 2, 5, and 6) with TRT (69.6 Gy delivered as 1.2 Gy twice-daily fractions beginning on day 1)
Number of subjects: 610
Study 19247655 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d aspirin
Number of subjects: 98
Study 16676655 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg, orally) administered after landing approximately 1 h before testing
Number of subjects: 5
Study 16676655 — intervention group
Group type: COMPARATOR
Intervention: Control (no midodrine)
Number of subjects: 5
Study 15316165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/day oral finasteride for 12 months
Number of subjects: 65
Study 15316165 — intervention group
Group type: COMPARATOR
Intervention: 5% topical minoxidil solution applied twice daily for 12 months
Number of subjects: 65
Study 10936980 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematil
Number of subjects: 75
Study 10936980 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 75
Study 10936980 — intervention group
Group type: EXPERIMENTAL
Intervention: Humana‐0
Number of subjects: 75
Study 10936980 — intervention group
Group type: COMPARATOR
Intervention: All formulas
Number of subjects: 75
Study 9355069 — intervention group
Group type: EXPERIMENTAL
Intervention: MCNS‐FSGS group
Number of subjects: 14
Study 9355069 — intervention group
Group type: EXPERIMENTAL
Intervention: FSGS‐R group (first biopsies during nephrotic stage)
Number of subjects: 14
Study 9355069 — intervention group
Group type: EXPERIMENTAL
Intervention: FSGS patients in remission
Number of subjects: 14
Study 9355069 — intervention group
Group type: COMPARATOR
Intervention: FSGS during nephrotic and remission stages
Number of subjects: 14
Study 1546900 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage (DG)
Number of subjects: 227
Study 1546900 — intervention group
Group type: COMPARATOR
Intervention: No drain (NDG)
Number of subjects: 227
Study 3838401 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine (2 mg intravenously)
Number of subjects: 30
Study 3838401 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (ISDN) (5 mg sublingually)
Number of subjects: 30
Study 3838401 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (20 mg sublingually)
Number of subjects: 30
Study 31612309 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 40
Study 31612309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 29969520 — intervention group
Group type: EXPERIMENTAL
Intervention: IATP-R
Number of subjects: 30
Study 27287235 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir monotherapy (50 mg/day)
Number of subjects: 28
Study 24933430 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO‐electrolyte solution
Number of subjects: 10
Study 24933430 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte (placebo) solution
Number of subjects: 10
Study 23509529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme Replacement Therapy (ERT)
Number of subjects: 18
Study 23509529 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian Fabry Disease Initiative (CFDI)
Number of subjects: 18
Study 23509529 — intervention group
Group type: EXPERIMENTAL
Intervention: CFDI
Number of subjects: 18
Study 19854432 — intervention group
Group type: EXPERIMENTAL
Intervention: Office ergonomics program implemented from 1995 to 2007
Number of subjects: 0
Study 19854432 — intervention group
Group type: EXPERIMENTAL
Intervention: Office ergonomics program with a 50-50 cost share agreement for office equipment purchases starting in 1999
Number of subjects: 0
Study 18157595 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphytum herb extract cream (10% active ingredient)
Number of subjects: 278
Study 18157595 — intervention group
Group type: COMPARATOR
Intervention: Reference product (1% active ingredient)
Number of subjects: 278
Study 16185409 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative charge aerosol (NCA) treatment for 1.5 hours, 1-2 times a day, from 6 postburn hours to 2 postburn days.
Number of subjects: 310
Study 16185409 — intervention group
Group type: COMPARATOR
Intervention: Negative charge aerosol (NCA) treatment in self control group with sterile schissel coverage.
Number of subjects: 310
Study 16185409 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative charge aerosol (NCA) treatment in trial group.
Number of subjects: 310
Study 16185409 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in control group.
Number of subjects: 310
Study 16185409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological examination in rats treated with NCA.
Number of subjects: 310
Study 16185409 — intervention group
Group type: COMPARATOR
Intervention: Pathological examination in rats treated with conventional treatment.
Number of subjects: 310
Study 12578249 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaphorical verbal instruction
Number of subjects: 60
Study 12578249 — intervention group
Group type: COMPARATOR
Intervention: Movement-relevant verbal instruction
Number of subjects: 60
Study 12578249 — intervention group
Group type: COMPARATOR
Intervention: None verbal instruction
Number of subjects: 60
Study 9720483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study 9720483 — intervention group
Group type: COMPARATOR
Intervention: Alpha-tocopherol (vitamin E)
Number of subjects: 0
Study 9720483 — intervention group
Group type: COMPARATOR
Intervention: Selegiline
Number of subjects: 0
Study 9720483 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal estrogen replacement
Number of subjects: 0
Study 9720483 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs
Number of subjects: 0
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring showing > 10 VEB/hour
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring showing couplets
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring showing nonsustained ventricular tachycardia (NSVT)
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring showing any complex ventricular arrhythmia
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular dysfunction
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent ventricular arrhythmias (VA)
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Couplets
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex ventricular arrhythmias (VA)
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsustained ventricular tachycardia (NSVT)
Number of subjects: 8676
Study 7642014 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall predictive power of ventricular arrhythmias (VA)
Number of subjects: 8676
Study 2769837 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration of middle ear effusions prior to ventilation tube insertion
Number of subjects: 55
Study 2769837 — intervention group
Group type: COMPARATOR
Intervention: Non-aspirated ears (control)
Number of subjects: 55
Study 320995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate ointment
Number of subjects: 0
Study 320995 — intervention group
Group type: COMPARATOR
Intervention: Flurandrenolone ointment
Number of subjects: 0
Study 31843628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study 31843628 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (remifentanil)
Number of subjects: 30
Study 30407136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 30407136 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study 30407136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30407136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (both drugs)
Number of subjects: 0
Study 29056008 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐2b (Y shape, 40 kD) injection (180 μg/week)
Number of subjects: 820
Study 29056008 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN‐α‐2a (control)
Number of subjects: 820
Study 26230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed physical exertion during recovery from concussion
Number of subjects: 0
Study 26230745 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of exertion
Number of subjects: 0
Study 26230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 0
Study 23809140 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)
Number of subjects: 35
Study 23809140 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleosidic reverse transcriptase inhibitor (NNRTI)
Number of subjects: 35
Study 20709708 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 95
Study 20709708 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous A1 pulley release
Number of subjects: 95
Study 19366774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened with adenosine‐stress radionuclide myocardial perfusion imaging (MPI)
Number of subjects: 1123
Study 19366774 — intervention group
Group type: COMPARATOR
Intervention: Not screened
Number of subjects: 1123
Study 19366774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened with normal MPI results
Number of subjects: 1123
Study 19366774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened with moderate or large MPI defects
Number of subjects: 1123
Study 19366774 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened
Number of subjects: 1123
Study 17014541 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III (self-etching priming agent)
Number of subjects: 60
Study 17014541 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid etch with Prime & Bond (traditional acid etch)
Number of subjects: 60
Study 15486377 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg/d
Number of subjects: 18
Study 15486377 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol, 50 microg bid
Number of subjects: 18
Study 11003204 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 23
Study 11003204 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 23
Study 11003204 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg/day (placebo)
Number of subjects: 23
Study 9306297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation and visualization treatment (6 hour-long sessions over 3 weeks)
Number of subjects: 76
Study 9306297 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational addiction treatment group
Number of subjects: 76
Study 9306297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (visualization and psychoeducation)
Number of subjects: 76
Study 9306297 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualization sessions
Number of subjects: 76
Study 8320604 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant administration
Number of subjects: 25
Study 8320604 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suctioning
Number of subjects: 25
Study 3578725 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3.0 micrograms/kg (group 1)
Number of subjects: 0
Study 3578725 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 0.1 mg/kg with fentanyl 3.0 micrograms/kg (group 2)
Number of subjects: 0
Study 3578725 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane 0.5% inspired concentration (group 3)
Number of subjects: 0
Study 29860964 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group cognitive behavioral stress management intervention
Number of subjects: 29
Study 29643261 — intervention group
Group type: EXPERIMENTAL
Intervention: EmboTrap device
Number of subjects: 227
Study 26612341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C, E, and Ferulic acid serum
Number of subjects: 15